念珠菌血症患者β-(1→3)-D-葡聚糖与甘露聚糖抗原动力学的详细研究
该前瞻性研究在德国两家三级医疗中心进行36个月,对131次念珠菌血症发作及15次复发共1243份血清检测BDG(Fungitell法)和Mn(Platelia Candida Ag-Plus法)。结果显示血培养采样前BDG和Mn已升高的比例分别为62.4%和30.8%,采样时敏感性分别为78.6%和35.1%。治疗应答与BDG和Mn水平下降相关(84.3%和70.5%),而BDG和Mn中位升高513 pg/mL和390 pg/mL提示复发(敏感性80%和46.7%)。
要点
- 血培养采样前BDG和Mn已升高的比例分别为62.4%和30.8%,抗原阳性常早于培养阳性。
- 治疗应答时BDG和Mn下降的比例分别为84.3%和70.5%。
- BDG中位升高513 pg/mL、Mn中位升高390 pg/mL提示复发,敏感性分别为80%和46.7%。
核心结论
- 念珠菌血症患者中真菌抗原阳性通常早于血培养阳性,复发多伴随抗原二次升高。
- BDG和Mn浓度上升预示致命结局,而下降提示多数患者预后良好。
研究设计与样本
- 前瞻性研究,在德国两家三级医疗中心进行36个月。
- 纳入成年念珠菌血症患者,共检测131次发作和15次复发的1243份血清。
- BDG采用Fungitell法检测,Mn采用Platelia Candida Ag-Plus法检测,密切随访临床病程与生物标志物动力学。
主要发现
- 血培养采样前BDG和Mn升高的比例分别为62.4%和30.8%。
- 血培养采样时BDG敏感性为78.6%,Mn敏感性为35.1%。
- 非存活者BDG水平显著高于存活者。
- 随访中治疗应答与BDG下降(84.3%)或Mn下降(70.5%)相关。
- BDG中位升高513 pg/mL、Mn中位升高390 pg/mL提示复发,敏感性分别为80%和46.7%。
关键数值与推荐
- BDG中位升高513 pg/mL提示复发,敏感性80%。
- Mn中位升高390 pg/mL提示复发,敏感性46.7%。
- 血培养采样时BDG敏感性78.6%,Mn敏感性35.1%。
临床怎么用
- 对念珠菌血症高危患者可监测BDG和Mn,抗原阳性常早于培养阳性。
- 治疗期间BDG和Mn下降提示治疗应答,水平再次升高需警惕复发。
- BDG和Mn上升预示致命结局风险增加,出院前应确认抗原下降或正常化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fungal antigens such as β-(1→3)-D-glucan (BDG) or mannan (Mn) are useful for detection of candidemia. However, detailed data on serum levels before diagnosis and during treatment are scarce. We conducted a prospective study at two German tertiary care centers for 36 months. Sera from adult patients with candidemia were tested for BDG (Fungitell assay) and Mn (Platelia Candida Ag-Plus assay). For each patient, the clinical course and biomarker kinetics were closely followed and compared. 1,243 sera from 131 candidemia episodes and 15 relapses were tested. In 35% of episodes, empirical therapy included an antifungal drug. Before blood culture sampling, BDG and Mn levels were elevated in 62.4% and 30.8% of patients, respectively. Sensitivity at blood culture sampling was 78.6% (BDG) and 35.1% (Mn). BDG levels of non-survivors were significantly higher than those of survivors. During follow-up, a therapeutic response was associated with decreasing BDG and Mn levels in 84.3% or 70.5% of episodes, respectively. A median increase of 513 pg BDG/mL and 390 pg Mn/mL indicated a relapse of candidemia with a sensitivity of 80% or 46.7%, respectively. In 72.9% and 46.8% of patients, increasing BDG or Mn levels were associated with a fatal outcome. Prior to discharge, BDG and Mn levels had dropped or normalized in 65.7% or 82.1% of patients, respectively. Summarising, in patients with candidemia, biomarker positivity usually precedes culture positivity. Relapses are mostly accompanied by secondary biomarker increases. Rising concentrations of BDG and Mn predict lethality, whereas decreasing levels suggest a favorable outcome in the majority of patients.
引用
- Träger J, Dräger S, Mihai S, et al. Detailed β-(1→3)-D-glucan and mannan antigen kinetics in patients with candidemia. J Clin Microbiol. 2023. PMID: 37823667. doi:10.1128/jcm.00598-23
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。